BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34137706)

  • 1. [Primary antifungal prophylaxis in oncohematological patients: who, when, and with what?].
    Herrera F; Salgueira C; Costantini P; Jordán R
    Medicina (B Aires); 2021; 81(3):438-451. PubMed ID: 34137706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
    Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
    Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
    Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
    Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
    Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens.
    Corzo-León DE; Satlin MJ; Soave R; Shore TB; Schuetz AN; Jacobs SE; Walsh TJ
    Mycoses; 2015 Jun; 58(6):325-36. PubMed ID: 25808822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
    Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive fungal infection in haematopoietic stem cell transplant recipients: epidemiology from the transplant physician's viewpoint.
    Bow EJ
    Mycopathologia; 2009 Dec; 168(6):283-97. PubMed ID: 19343534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point.
    Gonzalez AV; Ullmann AJ; Almyroudis NG; Segal BH
    J Natl Compr Canc Netw; 2008 Feb; 6(2):175-82. PubMed ID: 18319049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J
    Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
    McCoy D; Depestel DD; Carver PL
    Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fungal infections in hematopoietic stem cell transplantation in children at a pediatric children's hospital in Argentina.
    Gomez SM; Caniza M; Fynn A; Vescina C; Ruiz CD; Iglesias D; Sosa F; Sung L
    Transpl Infect Dis; 2018 Aug; 20(4):e12913. PubMed ID: 29679436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
    Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
    J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.
    Robenshtok E; Gafter-Gvili A; Goldberg E; Weinberger M; Yeshurun M; Leibovici L; Paul M
    J Clin Oncol; 2007 Dec; 25(34):5471-89. PubMed ID: 17909198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study.
    Marty FM; Lee SJ; Fahey MM; Alyea EP; Soiffer RJ; Antin JH; Baden LR
    Blood; 2003 Oct; 102(8):2768-76. PubMed ID: 12855583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
    Wasylyshyn A; Linder KA; Castillo CG; Zhou S; Kauffman CA; Miceli MH
    Mycopathologia; 2020 Apr; 185(2):299-306. PubMed ID: 31939052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
    Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
    Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
    Sarina B; Mariotti J; Bramanti S; Morabito L; Crocchiolo R; Rimondo A; Tordato F; Pocaterra D; Casari E; De Philippis C; Carlo-Stella C; Santoro A; Castagna L
    Transpl Infect Dis; 2018 Aug; 20(4):e12906. PubMed ID: 29668124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients.
    Martino R; Subirá M; Rovira M; Solano C; Vázquez L; Sanz GF; Urbano-Ispizua A; Brunet S; De la Cámara R;
    Br J Haematol; 2002 Feb; 116(2):475-82. PubMed ID: 11841455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation.
    Liu YC; Chien SH; Fan NW; Hu MH; Gau JP; Liu CJ; Yu YB; Liu CY; Hsiao LT; Liu JH; Chiou TJ; Chen PM; Tzeng CH
    J Microbiol Immunol Infect; 2016 Aug; 49(4):567-74. PubMed ID: 25735797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
    Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
    Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.